Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Pharma boosts Indian share markets
Fri, 1 Feb 09:30 am

The major Asian stock markets have opened the day on a mixed note with stock markets in Japan (up 0.4%) and Indonesia (up 1.2%) leading the gains. However, the stock markets in Hong Kong (down 0.4%) and South Korea (down 0.5%) faced selling pressure. The Indian share market indices have also opened the day on in the green. Barring FMCG and banking, all sectoral indices have opened in the green with stocks in the pharma and consumer durables leading the gains.

The Sensex today is up by around 46 points (0.2%), while the NSE-Nifty is up by around 9 points (0.2%). The mid cap and small cap stocks have also opened in the green with BSE Mid Cap index and BSE Small Cap indices up by around 0.4% each. The rupee is trading at Rs 53.32 to the US dollar.

Banking stocks have opened the mainly in the red with Allahabad Bank and Indian Bank leading the losses. However, Punjab National Bank (PNB) and Union Bank have opened in the green. Punjab National Bank (PNB) has announced its results for the third quarter of financial year 2013 (3QFY13). The total income for the quarter grew by 10.4% on a year on year (YoY) basis. The operating profits for the quarter grew marginally by 0.22% YoY. The net profit for the quarter registered a growth of 13.5% YoY. The growth in the bottomline was mainly driven by decrease in provisions against non-performing assets, higher cash recovery and reduction in cost of funds. The net interest margin (NIM) of the bank stood at 3.47 % at the end of the quarter. The gross nonperforming assets (NPAs) for the quarter increased to 4.61% versus 2.42% in 3QFY12.The net NPAs also rose to 2.56 % from 1.11 % in the 3QFY12. The Capital Adequacy Ratio (CAR) of the bank stood at 11.66 % at the end of the quarter.

Indian Pharma stocks have opened the day mainly in green with Panacea Biotech Ltd and Wockhardt Ltd leading the gains. The leading pharma company Lupin Ltd has announced its results for the third quarter of financial year 2013 (3QFY13). The sales for the quarter grew by 38% on a year on year (YoY) basis. This was mainly on account of robust growth in the sales in the US market. The operating profits for the quarter grew by 64.5% YoY with operating profit margins at 23.1%. The net profits for the quarter were up by 43% YoY. The growth in the bottomline was moderated due to the surge in tax expenses. Effective tax rate for the quarter stood at 38% as compared to 23% seen during the same period last year

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Pharma boosts Indian share markets". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.